MediMabBio is progressing towards clinical entry by partnering with Thermo Fisher Scientific for Contract Development and Manufacturing Organization (CDMO) Services. The venture, focused on monoclonal antibody-based liver cancer treatment, will utilize Thermo Fisher’s Quick to Clinic (QTC) solution to optimize development timelines and costs for their lead asset MMB101.
